183 related articles for article (PubMed ID: 11890649)
1. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
Van den Bosch F; Baeten D; Kruithof E; De Keyser F; Mielants H; Veys EM
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii33-6. PubMed ID: 11890649
[No Abstract] [Full Text] [Related]
2. Effects of anti-tumor necrosis factor alpha on synovium in patients with spondylarthropathy: comment on the article by Baeten et al.
Cunnane G
Arthritis Rheum; 2001 Dec; 44(12):2937-9. PubMed ID: 11762957
[No Abstract] [Full Text] [Related]
3. Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.
Schnarr S; Kuipers JG; Zeidler H
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S126-9. PubMed ID: 12463462
[TBL] [Abstract][Full Text] [Related]
4. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.
Kruithof E; Van den Bosch F; Baeten D; Herssens A; De Keyser F; Mielants H; Veys EM
Ann Rheum Dis; 2002 Mar; 61(3):207-12. PubMed ID: 11830424
[TBL] [Abstract][Full Text] [Related]
5. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha.
Allali F; Breban M; Porcher R; Maillefert JF; Dougados M; Roux C
Ann Rheum Dis; 2003 Apr; 62(4):347-9. PubMed ID: 12634235
[TBL] [Abstract][Full Text] [Related]
6. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations.
Generini S; Giacomelli R; Fedi R; Fulminis A; Pignone A; Frieri G; Del Rosso A; Viscido A; Galletti B; Fazzi M; Tonelli F; Matucci-Cerinic M
Ann Rheum Dis; 2004 Dec; 63(12):1664-9. PubMed ID: 15297279
[TBL] [Abstract][Full Text] [Related]
7. [Therapy for seronegative spondyloarthropathy].
Takasaki Y
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2437-43. PubMed ID: 19149042
[No Abstract] [Full Text] [Related]
8. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
St Clair EW
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
[No Abstract] [Full Text] [Related]
10. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases.
Kalden JR
Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856
[No Abstract] [Full Text] [Related]
11. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
Brandt J; Haibel H; Reddig J; Sieper J; Braun J
J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
[TBL] [Abstract][Full Text] [Related]
12. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
13. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Van den Bosch F; Kruithof E; Baeten D; De Keyser F; Mielants H; Veys EM
Ann Rheum Dis; 2000 Jun; 59(6):428-33. PubMed ID: 10834859
[TBL] [Abstract][Full Text] [Related]
14. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
Hirohata S
Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
[TBL] [Abstract][Full Text] [Related]
15. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
Harriman G; Harper LK; Schaible TF
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975
[No Abstract] [Full Text] [Related]
16. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.
Licata G; Pinto A; Tuttolomondo A; Banco A; Ciccia F; Ferrante A; Triolo G
Ann Rheum Dis; 2003 Mar; 62(3):280-1. PubMed ID: 12594127
[No Abstract] [Full Text] [Related]
17. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis.
Kruithof E; Kestelyn P; Elewaut C; Elewaut D; Van Den Bosch F; Mielants H; Veys EM; De Keyser F
Ann Rheum Dis; 2002 May; 61(5):470. PubMed ID: 11959776
[No Abstract] [Full Text] [Related]
18. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
Antoni C; Kalden JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
[TBL] [Abstract][Full Text] [Related]
19. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy.
Goossens PH; Verburg RJ; Breedveld FC
Ann Rheum Dis; 2001 Jun; 60(6):637. PubMed ID: 11350856
[No Abstract] [Full Text] [Related]
20. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
Baeten D; Kruithof E; Van den Bosch F; Van den Bossche N; Herssens A; Mielants H; De Keyser F; Veys EM
Ann Rheum Dis; 2003 Sep; 62(9):829-34. PubMed ID: 12922954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
